ZOHA SHAHZAD, OSAMA IJAZ, BADR ILMAGUOOK, RAHILA ALI, SADIA S. USMANI, ARSLAN A. KHAN, SAEEDA YASMIN, ABDUL MOIZ, FNU SAMRAH
{"title":"914-P: Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors and Nephrolithiasis—An Updated Meta-analysis","authors":"ZOHA SHAHZAD, OSAMA IJAZ, BADR ILMAGUOOK, RAHILA ALI, SADIA S. USMANI, ARSLAN A. KHAN, SAEEDA YASMIN, ABDUL MOIZ, FNU SAMRAH","doi":"10.2337/db25-914-p","DOIUrl":null,"url":null,"abstract":"Introduction and Objective: SGLT-2i are effective in treating type 2 diabetes (T2DM), promoting weight loss, reducing blood pressure, and lowering cardiovascular risk. Diabetes increases nephrolithiasis risk due to urine acidification and elevated oxalate concentrations. This meta-analysis evaluates the impact of SGLT-2i on nephrolithiasis incidence. Methods: A comprehensive search of Medline, Embase, Google Scholar, Cochrane CENTRAL, Scopus, and clinicaltrials.gov was conducted through November 2024. We included observational studies and RCTs comparing SGLT-2i to other diabetes medications or placebo. The primary outcome was nephrolithiasis incidence after treatment. A random-effects meta-analysis was performed to calculate the pooled odds ratio (OR). Results: Twenty-eight studies (75,371 participants) met the inclusion criteria. The pooled analysis showed that SGLT-2i significantly reduced the risk of nephrolithiasis compared to other medications or placebo (OR: 0.90; 95% CI: 0.83-0.98; p=0.02; I²=0%). This contrasts with a previous meta-analysis that found no association between SGLT-2i and nephrolithiasis. Conclusion: This updated meta-analysis shows that SGLT-2i reduce nephrolithiasis risk in T2DM, suggesting potential benefit for those with recurrent nephrolithiasis. These findings highlight the broader therapeutic benefits of SGLT-2i beyond glucose control. Disclosure Z. Shahzad: None. O. Ijaz: None. B. Ilmaguook: None. R. Ali: None. S.S. Usmani: None. A.A. Khan: None. S. Yasmin: None. A. Moiz: None. F. Samrah: None.","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"13 1","pages":""},"PeriodicalIF":7.5000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db25-914-p","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction and Objective: SGLT-2i are effective in treating type 2 diabetes (T2DM), promoting weight loss, reducing blood pressure, and lowering cardiovascular risk. Diabetes increases nephrolithiasis risk due to urine acidification and elevated oxalate concentrations. This meta-analysis evaluates the impact of SGLT-2i on nephrolithiasis incidence. Methods: A comprehensive search of Medline, Embase, Google Scholar, Cochrane CENTRAL, Scopus, and clinicaltrials.gov was conducted through November 2024. We included observational studies and RCTs comparing SGLT-2i to other diabetes medications or placebo. The primary outcome was nephrolithiasis incidence after treatment. A random-effects meta-analysis was performed to calculate the pooled odds ratio (OR). Results: Twenty-eight studies (75,371 participants) met the inclusion criteria. The pooled analysis showed that SGLT-2i significantly reduced the risk of nephrolithiasis compared to other medications or placebo (OR: 0.90; 95% CI: 0.83-0.98; p=0.02; I²=0%). This contrasts with a previous meta-analysis that found no association between SGLT-2i and nephrolithiasis. Conclusion: This updated meta-analysis shows that SGLT-2i reduce nephrolithiasis risk in T2DM, suggesting potential benefit for those with recurrent nephrolithiasis. These findings highlight the broader therapeutic benefits of SGLT-2i beyond glucose control. Disclosure Z. Shahzad: None. O. Ijaz: None. B. Ilmaguook: None. R. Ali: None. S.S. Usmani: None. A.A. Khan: None. S. Yasmin: None. A. Moiz: None. F. Samrah: None.
期刊介绍:
Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes.
However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.